Pemigatinib after standard chemo for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial studies whether adding pemigatinib after standard “7+3” chemotherapy can improve outcomes in certain newly diagnosed acute myeloid leukemia (AML) patients. It aims to find a safe dose and see how well the drug works in a very specific AML genetic group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to understand and sign consent
- Be newly diagnosed with AML (not the APL/M3 subtype) and be in the intermediate or adverse genetic risk group the study lists
- Have no FLT3 mutation that would normally qualify you for standard treatment with 7+3 plus midostaurin
- Be healthy enough for treatment (ECOG 0–2) and plan to have required bone marrow tests during the study
- Have adequate blood and organ test results, including kidney function, phosphate and blood minerals, bilirubin, and liver enzymes (they may need correction by the start of pemigatinib)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.